hypericin has been researched along with Cutaneous T-Cell Lymphoma in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma." | 9.14 | A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. ( Cabana, B; Duvic, M; Rook, AH; Tobia, A; Vonderheid, EC; Wood, GS, 2010) |
| "Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects." | 7.11 | Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. ( Akilov, O; Appel, J; Bhatia, N; Boh, E; Bohjanen, K; Carter, J; Dawes, K; DeSimone, JA; Donini, O; Duvic, M; Elston, D; Geskin, L; Girardi, M; Guitart, J; Haulenbeek, A; Huen, A; Kim, EJ; Kim, YH; Korman, NJ; Kuzel, TM; Lain, E; Lee, ST; Mangold, AR; Musiek, A; Nikbakht, N; Olsen, E; Pacheco, T; Pariser, D; Piette, W; Poligone, B; Pullion, C; Querfeld, C; Rook, AH; Rumage, A; Schaber, CJ; Seminario-Vidal, L; Shinohara, M; Straube, R; Wong, HK; Wood, GS; Zeitouni, N; Zwerner, JP, 2022) |
| "Hypericin is a known photodynamic agent that has been demonstrated to induce apoptosis in normal and malignant B and T lymphocytes, and has potential to treat benign and malignant disorders of the skin, including psoriasis and cutaneous T-cell lymphoma." | 5.14 | A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. ( Cabana, B; Duvic, M; Rook, AH; Tobia, A; Vonderheid, EC; Wood, GS, 2010) |
| "Given that mycosis fungoides-cutaneous T-cell lymphoma (MF/CTCL) is chronic, there is a need for additional therapies with minimal short- and long-term adverse effects." | 3.11 | Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. ( Akilov, O; Appel, J; Bhatia, N; Boh, E; Bohjanen, K; Carter, J; Dawes, K; DeSimone, JA; Donini, O; Duvic, M; Elston, D; Geskin, L; Girardi, M; Guitart, J; Haulenbeek, A; Huen, A; Kim, EJ; Kim, YH; Korman, NJ; Kuzel, TM; Lain, E; Lee, ST; Mangold, AR; Musiek, A; Nikbakht, N; Olsen, E; Pacheco, T; Pariser, D; Piette, W; Poligone, B; Pullion, C; Querfeld, C; Rook, AH; Rumage, A; Schaber, CJ; Seminario-Vidal, L; Shinohara, M; Straube, R; Wong, HK; Wood, GS; Zeitouni, N; Zwerner, JP, 2022) |
| "Hypericin is a photodynamic compound activated by either visible (400-700 nm) or UVA (320-400 nm) light, and has been shown to inhibit the growth of a variety of neoplastic cell types." | 1.30 | Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. ( Fox, FE; Niu, Z; Rook, AH; Tobia, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, EJ | 1 |
| Mangold, AR | 1 |
| DeSimone, JA | 1 |
| Wong, HK | 1 |
| Seminario-Vidal, L | 1 |
| Guitart, J | 1 |
| Appel, J | 1 |
| Geskin, L | 1 |
| Lain, E | 1 |
| Korman, NJ | 1 |
| Zeitouni, N | 1 |
| Nikbakht, N | 1 |
| Dawes, K | 1 |
| Akilov, O | 1 |
| Carter, J | 1 |
| Shinohara, M | 1 |
| Kuzel, TM | 1 |
| Piette, W | 1 |
| Bhatia, N | 1 |
| Musiek, A | 1 |
| Pariser, D | 1 |
| Kim, YH | 1 |
| Elston, D | 1 |
| Boh, E | 1 |
| Duvic, M | 2 |
| Huen, A | 1 |
| Pacheco, T | 1 |
| Zwerner, JP | 1 |
| Lee, ST | 1 |
| Girardi, M | 1 |
| Querfeld, C | 1 |
| Bohjanen, K | 1 |
| Olsen, E | 1 |
| Wood, GS | 2 |
| Rumage, A | 1 |
| Donini, O | 1 |
| Haulenbeek, A | 1 |
| Schaber, CJ | 1 |
| Straube, R | 1 |
| Pullion, C | 1 |
| Rook, AH | 3 |
| Poligone, B | 1 |
| Vonderheid, EC | 1 |
| Tobia, A | 2 |
| Cabana, B | 1 |
| Fox, FE | 1 |
| Niu, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma[NCT02448381] | Phase 3 | 169 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The proportion of patch lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions.~The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described." (NCT02448381)
Timeframe: 16 weeks
| Intervention | lesions with response (Number) |
|---|---|
| SGX301 (Cycle 1 & 2 = SGX301) | 65 |
| Placebo (Cycle 1) | 14 |
"The proportion of plaque lesions achieving a treatment response at Week 16 in the SGX301 treatment group compared to Week 8 in the Placebo treatment group. A treatment response was defined as a ≥50% improvement in CAILS score when compared to the CAILS score at baseline for individual lesions.~The Composite Assessment of Index Lesion Disease Severity (CAILS) score was measured as previously described." (NCT02448381)
Timeframe: 16 weeks
| Intervention | lesions with response (Number) |
|---|---|
| SGX301 (Cycle 1 & 2 = SGX301) | 64 |
| Placebo (Cycle 1) | 7 |
2 trials available for hypericin and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial.
Topics: Adult; Anthracenes; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoide | 2022 |
A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anthracenes; Antineoplastic Agents; Female; Humans | 2010 |
1 other study available for hypericin and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Cells, Cultured; Humans; Keratitis; Lymphocyte Activa | 1998 |